Author

Lana Pilja

Observed name: L. Pilja

Institution: Concert Pharmaceuticals (United States)

Observed institutions: Concert Pharmaceuticals (United States), Celldex Therapeutics (United States)

OpenAlex ID: A5028464061

Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development

2017 · Scott L. Harbeson, Adam J. Morgan, et al. · Journal of Pharmacology and Experimental Therapeutics · 85

Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies.

2014 · Stephen Maxted Ansell, Donald W. Northfelt, et al. · Journal of Clinical Oncology · 24

WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco ® in Phase I clinical studies

2016 · V. Uttamsineh, L. Pilja, et al. · Journal of Cystic Fibrosis · 13

Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors.

2014 · Jeffrey R. Infante, Howard A. Burris, et al. · Journal of Clinical Oncology · 12

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors

2013 · Howard Burris, Stephen Ansell, et al. · Journal for ImmunoTherapy of Cancer · 8

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors

2013 · Stephen Ansell, Donald Northfelt, et al. · Journal for ImmunoTherapy of Cancer · 7

Works count: 6

Citation count: 149

H-index: 6

I10-index: 4